Evolus posts scientific investor presentation on Jeuveau, Evolysse HA fillers, Profhilo skin-quality injectable portfolio
Reuters2026/08/05 22:12- Evolus highlighted a broader aesthetics portfolio built around Jeuveau neurotoxin, Evolysse hyaluronic acid fillers, and Profhilo skin-quality injections.
- Evolysse Form and Smooth showed non-inferiority at 6 months versus Restylane-L in a US pivotal nasolabial fold study of 140 patients.
- The primary endpoint analysis also showed statistical superiority at 6 months, with 95% CI [-0.5, -0.032] for Form, [-0.416, -0.019] for Smooth.
- Safety in the pivotal study was described as similar to control, with 0 serious adverse events and 0 delayed-onset nodules for both products.
- Profhilo was positioned as a European market-leading skin-quality injectable, cited as 4.8 million treatments across 70+ countries.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The higher the yen rises, the more retail investors short! 3.61 trillion yen short bets defy the trend, triggering a short squeeze warning
Even though the yen has reached its highest level in months, Japanese retail investors continue to bet that its sharp rebound will come to an end, and are consistently increasing their short positions.
EUR/USD Price Forecast: Bullish bias remains above 1.1600 ahead of ECB and US inflation
Abraxas Capital hedges $353M ETH short with $32M buy – Here’s why
Pinnacle Silver & Gold outlines fast-track plan to restart El Potrero gold-silver mine in Mexico
Crypto prices
More
